EcoDrugPlus

Cytochrome P450 3a40

Ensembl ID : ENSMZEG00005019844
Gene Symbol: LOC101478178
2 Cross references
518 Possible Orthologues:

Cytochrome P450 3a40

Ensembl ID : ENSMZEG00005019860
Gene Symbol: LOC101476786
2 Cross references
518 Possible Orthologues:

Cytochrome P450 3a40

Ensembl ID : ENSMZEG00005012181
Gene Symbol: LOC101471241
3 Cross references
541 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSMZEG00005027661
Gene Symbol: CYP19A1
4 Cross references
241 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSMZEG00005002429
Gene Symbol: CYP19A1
3 Cross references
242 Possible Orthologues:

Cytochrome P450, Family 17, Subfamily A, Polypeptide 1

Ensembl ID : ENSMZEG00005004704
Gene Symbol: CYP17A1
1 Cross references
209 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSMZEG00005012216
Gene Symbol: CYP3A65
1 Cross references
540 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSMZEG00005023816
Gene Symbol: LOC101475407
3 Cross references
196 Possible Orthologues:

Delta-Type Opioid Receptor

Ensembl ID : ENSMZEG00005027406
Gene Symbol: LOC101482911
3 Cross references
214 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSMZEG00005012700
Gene Symbol: LOC101474802
3 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSMZEG00005028249
Gene Symbol: LOC101487504
2 Cross references
188 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSMZEG00005026706
Gene Symbol: LOC101469920
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).